Chemistry:Tasipimidine
Tasipimidine (INN, USAN; developmental code names ODM-105 and ORM-19695), sold under the brand name Tessie, is an α2-adrenergic receptor agonist which is approved for the short-term treatment of fear and anxiety in dogs.[1][2] It is also under development for the treatment of insomnia in humans.[3][4][5] The drug is used as an oral solution in dogs,[1] whereas its route of administration for humans is unspecified.[4]
The drug acts as a potent and selective full agonist of the human α2A-adrenergic receptor.[3] Conversely, it is a much weaker agonist of the rodent α2B-, α2C-, and α2D-adrenergic receptors.[3] In addition, it shows only low affinity for α1-adrenergic receptors, where it appears to act as a partial agonist.[3] Tasipimidine produces anxiolytic, sedative, hypolocomotor, hypotensive, and bradycardic effects in animals.[3]
Tasipimidine is under development for use in humans by Orion Corporation.[4][5] As of October 2024, it is in phase 2 clinical trials for this indication.[4][5] The drug is or was also under development for the treatment of psychiatric disorders in humans, but no recent development for this indication has been reported.[4] It has reached phase 1 trials for psychiatric disorders.[4] Tasipimidine was approved for treatment of fear and anxiety in dogs in the European Union in 2021.[1]
See also
References
- ↑ 1.0 1.1 1.2 "Tessie 0.3 mg/ml oral solution for dogs". European Commission, Public Health. https://ec.europa.eu/health/documents/community-register/2024/20240606162589/anx_162589_en.pdf.
- ↑ "[New drugs for small animals in 2024]" (in German). Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere 53 (2): 103–110. April 2025. doi:10.1055/a-2559-6314. PMID 40233795.
- ↑ 3.0 3.1 3.2 3.3 3.4 "Tasipimidine-the pharmacological profile of a novel orally active selective α2A-adrenoceptor agonist". European Journal of Pharmacology 923. May 2022. doi:10.1016/j.ejphar.2022.174949. PMID 35405115.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 "Tasipimidine". 28 October 2024. https://adisinsight.springer.com/drugs/800070674.
- ↑ 5.0 5.1 5.2 "Delving into the Latest Updates on Tasipimidine with Synapse". 28 June 2025. https://synapse.patsnap.com/drug/a2741ddb7ef748a594131b1373386489.
 |  |
